Diabetes drugs battle to control silent liver epidemic
NCT ID NCT07363707
Summary
This study compared two diabetes medications, dapagliflozin and empagliflozin, to see which works better for treating fatty liver disease in people with type 2 diabetes. Researchers followed 108 adults for six months, measuring liver fat and scarring using special scans and blood tests. The goal was to determine if adding either drug to standard metformin treatment could help control both diabetes and the related liver condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NAFLD (NONALCOHOLIC FATTY LIVER DISEASE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beni Suef University Hospital
Cairo, Egypt
Conditions
Explore the condition pages connected to this study.